Mineralys Therapeutics (MLYS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.25B and a free-cash-flow yield of -14.9%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Trailing · -49.6% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-71.3%
How far the last close sits under the highest price of the past five years.
Market cap
$1.25B
Trailing P/E
—
Price / book
2.5
Price / sales
—
FCF yield
-14.9%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.8
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MLYS earnings
Next report: Feb 11, 2027 (Q4 2026, EPS estimate -$0.67).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
-$0.64
-$0.55
-16.4%
$0
Q2 2026
Aug 11, 2026
-$2.85
-$0.53
-437.7%
$0
Q1 2026
May 6, 2026
-$0.47
-$0.44
-6.8%
$0
Q4 2025
Mar 12, 2026
-$0.40
-$0.52
+23.1%
$0
MLYS analyst price target
Median target $52.00 from 9 analysts, ranging $19.00 – $56.00.
Nama's AI scorecard currently rates Mineralys Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MLYS report earnings?
Mineralys Therapeutics's next scheduled report is on Feb 11, 2027. Analysts expect EPS of -$0.67.
What is the MLYS price target?
The median analyst price target from 9 analysts is $52.00, with a range of $19.00 – $56.00.
Is MLYS Shariah compliant?
Nama's AAOIFI-style screen reads Mineralys Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.